Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
JD Health International, Inc. ( (HK:6618) ) has shared an update.
JD Health International Inc. announced significant changes in its board of directors and remuneration committee. Mr. Enlin Jin and Mr. Qingqing Yi have resigned from their positions due to personal and professional commitments, respectively. Mr. Dong Cao has been appointed as the new executive director and CEO, bringing extensive experience from his previous roles within the JD Group. These changes are expected to impact the company’s strategic direction and governance, potentially influencing its market positioning and stakeholder relations.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$78.50 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
More about JD Health International, Inc.
JD Health International Inc. operates in the healthcare industry, providing a range of health-related services and products. The company is part of the JD Group and focuses on leveraging technology to enhance healthcare delivery and accessibility.
Average Trading Volume: 9,992,197
Technical Sentiment Signal: Buy
Current Market Cap: HK$206.5B
For a thorough assessment of 6618 stock, go to TipRanks’ Stock Analysis page.